STOCK TITAN

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management

Allogene Therapeutics (ALLO) announced the passing of founding board member David Bonderman at age 82. Bonderman, who served as Lead Independent Director since the company's founding in 2018, was instrumental in advancing CAR T-cell therapy development. He was an early supporter of Kite Pharma and later helped establish and guide Allogene's evolution in developing allogeneic CAR T products for cancer and autoimmune disease treatment. His role as a champion of innovation and trusted mentor made significant contributions to the company's development in pioneering AlloCAR T™ products.

Allogene Therapeutics (ALLO) ha annunciato la scomparsa del membro fondatore del consiglio David Bonderman all'età di 82 anni. Bonderman, che ha ricoperto il ruolo di Direttore Indipendente Principale sin dalla fondazione dell'azienda nel 2018, è stato fondamentale per l'avanzamento dello sviluppo della terapia con CAR T-cell. È stato un sostenitore precoce di Kite Pharma e in seguito ha contribuito a stabilire e guidare l'evoluzione di Allogene nello sviluppo di prodotti CAR T allogenici per il trattamento del cancro e delle malattie autoimmuni. Il suo ruolo di sostenitore dell'innovazione e mentore fidato ha dato un contributo significativo allo sviluppo dell'azienda nel pioniere dei prodotti AlloCAR T™.

Allogene Therapeutics (ALLO) anunció el fallecimiento del miembro fundador de la junta David Bonderman a los 82 años. Bonderman, quien se desempeñó como Director Independiente Principal desde la fundación de la empresa en 2018, fue fundamental en el avance del desarrollo de la terapia CAR T-cell. Fue un temprano partidario de Kite Pharma y luego ayudó a establecer y guiar la evolución de Allogene en el desarrollo de productos CAR T alogénicos para el tratamiento del cáncer y enfermedades autoinmunes. Su papel como defensor de la innovación y mentor de confianza hizo contribuciones significativas al desarrollo de la empresa en la creación de productos AlloCAR T™.

Allogene Therapeutics (ALLO)는 창립 이사 중 한 명인 David Bonderman이 82세에 세상을 떠났다고 발표했습니다. Bonderman은 2018년 회사 설립 이후 독립 이사로 활동하면서 CAR T 세포 치료 개발을 촉진하는 데 중요한 역할을 했습니다. 그는 Kite Pharma의 초기 지지자였으며, 이후 Allogene의 발전을 돕고 암 및 자가 면역 질환 치료를 위한 동종 CAR T 제품 개발을 이끌었습니다. 혁신의 옹호자이자 신뢰할 수 있는 멘토로서의 그의 역할은 AlloCAR T™ 제품 개발에 있어 회사의 발전에 중요한 기여를 했습니다.

Allogene Therapeutics (ALLO) a annoncé le décès de son membre fondateur du conseil David Bonderman à l'âge de 82 ans. Bonderman, qui a exercé la fonction de Directeur Indépendant Principal depuis la création de l'entreprise en 2018, a été essentiel dans l'avancement du développement de la thérapie CAR T-cell. Il a été un soutien précoce de Kite Pharma et a ensuite aidé à établir et à guider l'évolution d'Allogene dans le développement de produits CAR T allogéniques pour le traitement du cancer et des maladies auto-immunes. Son rôle de promoteur de l'innovation et de mentor de confiance a apporté des contributions significatives au développement de l'entreprise dans la création de produits AlloCAR T™.

Allogene Therapeutics (ALLO) gab den Tod des Gründungsmitglieds des Vorstands David Bonderman im Alter von 82 Jahren bekannt. Bonderman, der seit der Gründung des Unternehmens im Jahr 2018 als Leitender Unabhängiger Direktor tätig war, spielte eine entscheidende Rolle bei der Förderung der Entwicklung der CAR T-Zelltherapie. Er war ein früher Unterstützer von Kite Pharma und half später, die Evolution von Allogene bei der Entwicklung von allogenen CAR T-Produkten zur Behandlung von Krebs und Autoimmunerkrankungen zu gestalten. Seine Rolle als Innovator und vertrauenswürdiger Mentor leistete bedeutende Beiträge zur Entwicklung des Unternehmens im Bereich der bahnbrechenden AlloCAR T™ Produkte.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today acknowledged the passing of founding board member, David Bonderman. David died at the age of 82, surrounded by his family.

“We are deeply saddened by the passing of our founding board member and dear friend,” said Arie Belldegrun, M.D., Executive Chairman and Co-Founder of Allogene. “David was more than a board member – he was a champion of innovation, a trusted mentor, and an enduring source of inspiration to all of us. He was also an unwavering believer in the groundbreaking potential of CAR T therapy. Long before Allogene was founded, David recognized the promise of this innovative approach, becoming one of the earliest advocates and supporters of Kite Pharma. His passion and dedication only deepened over time as he helped to guide the establishment and evolution of Allogene. Words cannot express how much he will be missed.”

A steadfast advocate for CAR T-cell therapy, David’s contributions to Allogene are immeasurable. He served on Allogene’s Board of Directors since its founding in 2018, taking on the role of Lead Independent Director. In this capacity, he championed innovation, provided trusted mentorship, and served as a constant source of inspiration to all who worked alongside him.

“David’s contributions to Allogene were immeasurable. His wisdom, guidance, and steadfast commitment to revolutionizing cancer treatment have left an indelible mark on Allogene, the field of CAR T, and the world of science,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “Our deepest sympathies go out to the Bonderman family and all of those who were fortunate to know him. We join them in honoring a remarkable man whose contributions will continue to save lives and bring transformative treatments to those in need, leaving an enduring legacy in the world of human health.”

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

AlloCAR T is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com


FAQ

Who was David Bonderman and what was his role at Allogene Therapeutics (ALLO)?

David Bonderman was a founding board member of Allogene Therapeutics who served as Lead Independent Director since 2018. He was an early advocate of CAR T therapy and played a important role in the company's establishment and development.

When did Allogene Therapeutics (ALLO) founding board member David Bonderman pass away?

David Bonderman passed away in December 2023 at the age of 82, surrounded by his family.

What is Allogene Therapeutics (ALLO) main focus in product development?

Allogene Therapeutics is a clinical-stage biotechnology company focused on pioneering the development of allogeneic CAR T (AlloCAR T™) products for treating cancer and autoimmune disease.

When was Allogene Therapeutics (ALLO) founded?

Allogene Therapeutics was founded in 2018, with David Bonderman serving as a founding board member and Lead Independent Director.

Allogene Therapeutics

NASDAQ:ALLO

ALLO Rankings

ALLO Latest News

ALLO Stock Data

472.81M
144.50M
18.07%
80.43%
15.43%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO